
USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$141.82M
Market Cap
-
P/E Ratio
-0.59
EPS
$2.90
52 Week High
$1.05
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$82M |
| Selling General And Administrative | $16M |
| Research And Development | $14M |
| Operating Expenses | $82M |
| Investment Income Net | - |
| Net Interest Income | $8.1M |
| Interest Income | $8.1M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$74M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$74M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$82M |
| Ebitda | -$30M |
| Net Income | -$74M |
| Field | Value (USD) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$82M |
| Selling General And Administrative | $16M |
| Research And Development | $14M |
| Operating Expenses | $82M |
| Investment Income Net | - |
| Net Interest Income | $8.1M |
| Interest Income | $8.1M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | - |
| Income Before Tax | -$74M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$74M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$82M |
| Ebitda | -$30M |
| Net Income | -$74M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Climb Bio, Inc. is a biotechnology company based in Wilmington, Delaware, specializing in the development of innovative therapies for autoimmune-driven inflammatory diseases. With a strong and diverse pipeline of drug candidates, Climb Bio harnesses advanced scientific research to address significant unmet medical needs in this therapeutic area. The company’s strategic focus on research and development, combined with its commitment to enhancing patient outcomes, establishes Climb Bio as a vital entity within the biotechnology field, poised for potential growth and impact in the industry.